London, 27th April 2006 -- The 2006 Frost & Sullivan Product Innovation Award for the European primary care diagnostics market is conferred on Canada-based Ceapro Inc in recognition of its pioneering point-of-care (POC) based type 2 diabetes and pre-diabetes diagnostic product. The company’s CeaProve™ represents a breakthrough in diabetes screening, diagnosis and monitoring.

“CeaProve™ is an innovative and unique product with the ability to identify diabetes at an early phase or at the pre-diabetes stage itself,” notes Frost & Sullivan Research Analyst Dr. Fiona Rahman. “The motivation behind CeaProve™’s development is that early detection means earlier intervention in order to better manage, prevent or delay diabetes and mitigate its effects as well as that of associated complications.”

Feedback has shown that 15-20 per cent of patients who have used the product and subsequently altered their lifestyle have experienced dramatically positive results. The turn- around time from pre-diabetic blood sugar levels to normal blood sugar levels occurs in 6-8 weeks, illustrating that it is possible to reverse a pre diabetic condition if detected early enough.
The increased use of POC testing, particularly in the primary care sector, is anticipated to result in improved healthcare delivery and lowered costs over the long term. In this regard, Ceapro Inc has consistently leveraged its core expertise in POC testing, particularly in the diabetes POC segment.

In conjunction with healthcare providers and business owners, Ceapro Inc has launched diabetes screening initiatives, which are widely anticipated to result in significant cost benefits over the long term. Such an approach has also underlined the company’s key role in the promotion of POC diabetes testing and the development of the POC market as a whole.

“By capitalising on its leading roles in both existing and niche markets, Ceapro Inc is well positioned to maintain itself at the centre of the diabetes diagnostic POC segment by supplying innovative concepts, which will cater to the expected growth in demand for point-of-care solutions,” says Dr. Rahman. “This will give the company a competitive advantage as established in-vitro diagnostics (IVD) competitors focus mainly on conventional laboratory-based tests.”

The Frost & Sullivan Award for Product Innovation is presented each year to the company that has demonstrated excellence in new products and technologies within their industry. The recipient company has shown innovation by launching a broad line of emerging products and technologies.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
For further information, please contact

Kristina Menzefricke
Frost & Sullivan
Promotions Manager, Best Practices EMEA
kristina.menzefricke@frost.com
Tel. +44 (0) 20 7343 8376